<PAGE> 1
==================================================
Securities and Exchange Commission
Washington, D.C. 20549
------------------------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) October 17, 1996
HEALTHCARE ACQUISITION CORP.
(Exact name of registrant as specified in its charter)
<TABLE>
<S> <C> <C>
Delaware 65-0572565 0-26538
(State or other jurisdiction of incorporation) (I.R.S. Identification No.) (Commission File No.)
200 East Broward Blvd., P.O. Box 1900 33301
Fort Lauderdale, Florida (Zip Code)
(Address of principal executive office)
</TABLE>
Registrant's telephone number, including area code: (954) 761-2908
================================================
<PAGE> 2
ITEM 5. OTHER EVENTS
On October 17, 1996, Healthcare Acquisition Corp. ("Registrant") and
Encore Orthopedics, Inc., a Texas corporation ("Encore"), announced that they
had entered into a letter of intent dated October 11, 1996 ("Letter of Intent")
with respect to the proposed merger of a subsidiary to be formed by Registrant
with and into Encore, with Encore being the surviving corporation and becoming a
wholly-owned subsidiary of the Registrant.
A copy of the Letter of Intent is attached as an exhibit to this Report
on Form 8-K and is hereby incorporated by this reference. The consummation of
the transactions contemplated by the Letter of Intent is subject, among other
conditions, to the execution and delivery by the Registrant and Encore of a
definitive merger agreement ("Definitive Merger Agreement"). The Definitive
Merger Agreement may contain terms and conditions for the proposed transactions
that are in addition to or are different from the terms and conditions set forth
in the Letter of Intent. The consummation of the transactions contemplated by
the Definitive Merger Agreement will also be subject to the prior approval of
the stockholders of the Registrant and Encore.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS
(c) The following documents are filed herewith as exhibits:
2.1 Letter of Intent dated October 11, 1996
99.1 Press Release dated October 17, 1996
2
<PAGE> 3
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
HEALTHCARE ACQUISITION CORP.
/s/ John H. Abeles
--------------------------
Name: John H. Abeles
Title: President
Dated: October 22, 1996
3
<PAGE> 1
Exhibit 2.1
Encore Orthopedics, Inc.
8900 Shoal Creek Boulevard
Building 300
Austin, Texas 78757
Attention: Nicholas Cindrich,
Chairman of the Board of Directors
and Chief Executive Officer
October 11, 1996
Ladies and Gentlemen:
This Letter of Intent describes our understanding as to a proposed
transaction pursuant to which Encore Orthopedics, Inc. will conclude a merger
("Merger") with a newly formed subsidiary of Healthcare Acquisition Corp.
1. The Parties.
A. Healthcare Acquisition Corp., a Delaware corporation,("Healthcare").
B. HCAC Acquisition Company, a Texas corporation to be formed
("Acquisition Co."), the issued and outstanding capital stock of which will be
common stock ("Acquisition Common Stock") owned solely by Healthcare.
C. Encore Orthopedics, Inc., a Texas corporation ("Encore"). Encore's
authorized capital stock consists of 15,000,000 shares of common stock, $0.01
par value ("Encore Common Stock"), and 5,000,000 shares of Preferred Stock, par
value $1.00 ("Encore Preferred Stock"), 1,000,000 shares of which have been
designated as Series A Preferred Stock. In addition, Encore has issued warrants
and options (including, but not limited to, options under certain stock option
plans) that are currently outstanding (collectively, the "Encore Warrants"). All
Encore Warrants other than those identified on Exhibit A hereto, are hereinafter
referred to as the "Encore Included Warrants," and all the Encore Warrants
identified on Exhibit A hereto are hereinafter referred to as the "Encore
Excluded Warrants."
2. The Merger.
On the effective date ("Effective Date") of the Merger (currently anticipated to
occur on or about December 31, 1996), and pursuant to the definitive Merger
Agreement ("Merger Agreement") described below, Encore and Acquisition will
merge with one another in a statutory merger under Texas law in which Encore
will be the surviving entity. Upon consummation of the Merger, the
<PAGE> 2
Board of Directors of Healthcare will consist of Joel Kanter, Jay Haft and John
Abeles, plus seven additional board members designated by Encore in the Merger
Agreement and its officers will be designated by Encore in the Merger Agreement
from among its current officers. It is contemplated that, upon consummation of
the Merger, Healthcare will change its name to one that includes the "Encore"
mark.
3. Conversion of Securities.
On the Effective Date, all the Acquisition Common Stock will be converted on a
one share-for-one share basis into common stock of the surviving entity, and the
surviving entity will become a wholly owned subsidiary of Healthcare. On the
Effective Date, the Encore Common Stock, Encore Preferred Stock and Encore
Warrants shall be converted as follows:
A. Encore Common Stock, Encore Preferred Stock and Encore Included
Warrants.
(1) Holders of Encore Common Stock and Encore Preferred Stock
will receive, upon conversion of those securities in the Merger, shares of
Healthcare common stock, $.001par value ("Healthcare Common Stock") and New
Healthcare $7.00 Warrants (as described below). Each Encore Included Warrant
shall, by virtue of the Merger, cease to be exercisable for Encore Common Stock
and shall instead be exercisable for one Unit (as hereinafter defined) for each
share of Encore Common Stock for which it was exercisable immediately prior to
the Merger. A "Unit" shall be the number of shares of Healthcare Common Stock
and New Healthcare $7.00 Warrants into which a share of Encore Common Stock is
converted by virtue of the Merger. The total number of shares of Healthcare
Common Stock available for issuance upon conversion of the Encore Common Stock
and Encore Preferred Stock in the Merger and upon exercise of the Encore
Included Warrants ("New Healthcare Common Stock") shall be, collectively, that
number of shares of Healthcare Common Stock that is equal to the amount obtained
by dividing $40,000,000 by the Per Share Amount (as hereinafter defined). The
"Per Share Amount" shall be equal to Healthcare's cash on hand as of the
Effective Date (including the amounts held in trust that will be distributed to
Healthcare upon consummation of the Merger) divided by the total issued and
outstanding Healthcare Common Stock as of the Effective Date (but prior to the
Merger). The "New Healthcare $7.00 Warrants" shall be warrants for Healthcare
Common Stock at an exercise price of $7.00 per share, and will be exercisable
for a period of four years beginning on the Effective Date. The total number of
shares of Healthcare Common Stock underlying those certain New Healthcare $7.00
Warrants to be issued in the Merger upon conversion of the Encore Common Stock
or Encore Preferred Stock and those certain New Healthcare $7.00 Warrants
issuable upon exercise of the Encore Included Warrants, collectively, shall be
equal to 15% of the number of shares of New Healthcare Common Stock.
(2) An amount of the New Healthcare Common Stock issued in
exchange for the Encore Common Stock equal to 10% of all the New Healthcare
Common Stock ("Escrow Stock") shall be delivered by certain principal Encore
shareholders to be identified in the Merger Agreement to an escrow agent to be
appointed by the parties, and shall be held in escrow pending completion
<PAGE> 3
of the audit of Encore's financial statements for its fiscal year ending
December 31, 1996 ("1996 Financial Statements"). If Encore's sales for 1996 as
reflected in the 1996 Financial Statements ("1996 Sales"), are less than
$16,200,000, Escrow Stock shall be forfeited to the Company for cancellation and
return to the Company's authorized but unissued common stock. The number of
shares of Escrow Stock to be so forfeited shall be the amount obtained by
dividing (i) the product of 2.22 multiplied by the amount by which 1996 Sales is
less than $16,200,000; by (ii) the Per Share Amount. The foregoing calculation
shall be made promptly after the audit of the 1996 Financial Statements, and,
promptly thereafter, the remaining Escrow Stock will be distributed to its
owners. The order of forfeiture of Escrow Stock, and appropriate indemnities and
releases from the holders of Escrow Stock, will be set forth in the Escrow
Agreement with respect thereto to be entered into at or prior to the Effective
Date.
(3) The definitive Merger Agreement (described below) shall
set forth the precise manner in which the New Healthcare Common Stock and New
Healthcare $7.00 Warrants will be converted. Encore shall assure that the number
of shares of Healthcare Common Stock and New Healthcare $7.00 Warrants issuable
upon exercise of all the Encore Warrants complies with the terms of the Encore
Warrants.
B. Encore Excluded Warrants. The Encore Excluded Warrants will cease to
be exercisable for Encore Common Stock. Each Encore Excluded Warrant shall
thereafter be exercisable for one Unit per each share of Encore Common Stock for
which it was exercisable immediately prior to the Merger, and the exercise price
per Unit shall be the exercise price per share of Encore Common Stock in effect
immediately prior to the Merger. The Encore Excluded Warrants and the Encore
Included Warrants and the plans, if any, under which they were issued will be
amended to the extent necessary to accomplish the foregoing and to reduce the
number of options authorized under such plan to those that have been issued as
of the Effective Date.
4. Adoption of Stock Option Plan.
The Merger Agreement will provide that, upon the Effective Date, Healthcare will
adopt one or more Stock Option Plan(s) for employees and such other persons,
providing for the issuance of such Healthcare Common Stock options as shall be
determined by agreement of the parties and set forth in the Merger Agreement.
5. Definitive Agreement.
The transactions contemplated by this Letter of Intent are subject to the
execution by all parties of the definitive Merger Agreement superseding this
Letter of Intent and providing for the transactions contemplated herein. The
Merger Agreement will include such representations and warranties, covenants,
indemnities, and conditions, and require such legal opinions and certificates of
officers of the parties as is customary in transactions of this nature.
Conditions precedent to the Merger will include the following:
<PAGE> 4
A. Authorization. The transactions contemplated by the Merger Agreement
shall have been approved by all requisite action on the part of the shareholders
and directors of the respective parties. Encore has reviewed a copy of
Healthcare's prospectus dated March 8, 1996, which describes conditions that
must be satisfied before the Merger can be consummated and acknowledges that the
satisfaction of each of these conditions will be preconditions to the Merger.
B. Tax Opinion. Each party shall have received a tax opinion in a form
and substance satisfactory to such party that the transaction will constitute a
"tax free reorganization" pursuant to Section 368(a) of the Internal Revenue
Code of 1986, as amended.
C. Registration. A registration statement on Form S-4, containing a
combined proxy statement and prospectus providing for the approval of the
transaction by the stockholders of Healthcare and Encore and the issuance of
the securities of Healthcare to be issued upon consummation of the Merger,
shall have been filed with and declared effective by the Securities and
Exchange Commission, and such actions as are necessary under State Blue Sky or
securities laws to permit the issuance of such securities shall have been
taken.
D. Lock Up Agreements. Receipt by Healthcare of Agreements not to sell,
transfer, pledge or otherwise dispose of any Healthcare Common Stock or warrants
therefor from each Encore shareholder who, upon consummation of the Merger, will
own, have the right to acquire, or otherwise be the "beneficial owner" (as
defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) of
over 5,000 shares of Healthcare Common Stock. Each Lock Up Agreement will
provide for the release of the securities restricted thereby based upon the
number of shares of Healthcare Common Stock such shareholder will own, have the
right to acquire or be the beneficial owner of, upon consummation of the Merger
(except as otherwise provided in 5.D.(3) below), as follows:
(1) Between 5,001 through 99,999 shares - one-half released
after 9 months and one-half released after 1 year.
(2) 100,000 shares or more - one-third released after 12
months, one-third released after 15 months, and one-third released after 18
months; and
(3) Senior management and the major shareholders (the
Turanyis', Wolfgang Schweizer, Helmut Vogel and Michael Pentopoulos) -
one-fourth released after 12 months, one-fourth released after 15 months,
one-fourth released after 18 months, and one-fourth released after 24 months.
E. Encore Warrants. All Encore Warrants that cannot be converted as
provided in Section 4 hereof without the consent of the holder thereof, must
have been tendered by the holder thereof for exchange in accordance with
Section 4.
F. Sales Target. Encore's sales for the 9 month period ended September
27, 1996 shall have been at least $11,400,000 and Encore shall have delivered
to Healthcare an unaudited income
<PAGE> 5
statement reflecting same, certified as true by the President of Encore and
reviewed by Price Waterhouse.
G. Elimination of All "Put" Rights. All rights of any shareholder,
warrant holder or other security holder to require Encore or its successors to
pay any amount (including, but not limited to, the "put" rights of Sirrom under
its Encore Warrants) in cash or property upon surrender of such security and
shall have been released.
H. Fairness Opinion. Each party shall have received a fairness opinion
from a qualified investment banker of its selection to the effect that the
Merger is fair to such party's shareholders from a financial point of view.
6. Investigation.
Each party shall afford to the officers, employees, accountants, counsel and
other authorized representatives of the other, reasonable access to its
properties, books and records and shall use its best efforts to cause its
representatives to furnish such additional financial and operating data and
other information as the other may from time to time reasonably request for the
purpose of conducting a due diligence investigation. Each party shall be
authorized to conduct thorough background investigations regarding the officers
and directors of the other parties hereto, and if requested by another party
hereto, each party shall obtain written authorization from their officers and
directors permitting such investigations.
7. Ordinary Course.
From the date hereof until the execution of the definitive Merger Agreement,
closing of the transaction contemplated hereby or the termination of this Letter
of Intent, neither party will, without first consulting with the other party
hereto, (i) make any change in the conduct of its business, (ii) enter into any
transaction other than in the ordinary course of business, (iii) except in the
ordinary course of business, dispose of any of its assets, (iv) subject any of
its assets to a lien or other encumbrance except in the ordinary course of
business, (v) waive any right of substantial value, (vi) make any changes in any
employment arrangements, or (vii) make any changes in its capital structure or
issue any additional shares (other than pursuant to the exercise of outstanding
options, warrants, subscriptions, agreements or commitments giving anyone the
right to acquire shares of capital stock or granting options at an exercise
price of $5.00 or more to distributors or surgeons under current Encore plans
not to exceed the amounts currently authorized thereunder).
8. No Solicitation.
From the date hereof until the date upon which this Letter of Intent is
terminated, neither party will, directly or indirectly, without the prior
written consent of the other party hereto, (i) solicit, initiate or encourage
submission of proposals or offers from any third party relating to any
acquisition or purchase of all or a material portion of the assets of, or any
equity interest in, such party, or any merger, consolidation or business
combination with such third party or its designee, or (ii) except
<PAGE> 6
to the extent required by fiduciary obligations under applicable law as advised
in writing by counsel, participate in any discussions or negotiations regarding,
or furnish to any third party any information with respect to any of the
foregoing. Each party shall promptly notify the other party of any such
proposal, offer, inquiries made, providing reasonable detail of the identity of
the third party and the terms and conditions of the proposal or offer.
9. Announcement.
Encore understands and acknowledges that Healthcare and its affiliates will make
a public announcement of the proposed transaction immediately following the
execution of this Letter of Intent and will file this Letter of Intent with the
Securities and Exchange Commission. Healthcare agrees that, to the extent
practicable, Encore shall have the right to review and provide Healthcare with
its comments on such public announcement. In addition, Healthcare and Encore
will work together to prepare an announcement for release by Encore that is
mutually agreeable to Healthcare and Encore. To the extent practicable, except
as required by law or stock exchange rules and regulations, neither party shall
make any other public disclosure or announcement regarding the transactions
contemplated by this Letter of Intent (other than to announce its expiration)
without the consent of the other party (which consent shall not be unreasonably
withheld.).
10. No Violations.
Subject to receipt of required consents to the transactions contemplated from
third party lenders, lessors and other customary consents, each party hereby
represents and warrants to the other party hereto that the execution, delivery
and performance by such party of this Letter of Intent and the consummation by
such party of the transactions contemplated hereby, do not and will not
constitute a violation of or default under (either immediately, upon notice or
upon lapse of time) any provision of any contract or agreement to which such
party is bound.
11. Joint Drafting Responsibility.
This Letter of Intent is the result of the joint efforts and negotiations of the
parties hereto, with each party being represented or having the opportunity to
be represented by legal counsel of its own choice. The parties agree that the
rule of judicial interpretation to the effect that any ambiguity or uncertainty
contained in an agreement is to be construed against the party who drafted the
agreement shall not be applied in the event of any disagreement or dispute
arising out of this Letter of Intent.
12. Expenses and Brokers.
Each of the parties hereto agrees to pay its own expenses in connection with the
matters contemplated hereby, without regard to whether a transaction is
consummated. In addition, each party represents and warrants to the other that
it has not retained a finder or broker in connection with the transactions
contemplated hereby and that no broker's or finder's fee is or shall become due
to any third party upon consummation of a business transaction between the
parties.
<PAGE> 7
13. Binding Effect.
This Letter of Intent is intended to evidence the current intentions of the
parties with respect to the transactions contemplated hereby as reflected in
discussions between us to date, and it is expressly understood and agreed that
this Letter of Intent does not constitute an agreement to consummate the
transactions contemplated hereby or to enter into the Merger Agreement, and the
parties hereto have no rights or obligations of any kind whatsoever relating to
the transactions contemplated hereby unless and until the Merger Agreement is
executed and delivered; provided, however, that the respective obligations of
Healthcare and Encore contained in this Section and Sections 6,7,8,9,10,11 and
12 will be binding upon such party when each has signed this Letter of Intent in
the manner provided below. This Letter of Intent may be terminated by either
party upon written notice to the other.
If the above proposal is acceptable to you, please so indicate in the
space provided below and return one executed copy to the undersigned. This
Letter of Intent may be executed in one or more counterparts, each of which
shall be deemed an original, and all of which will constitute one and the same
instrument.
Sincerely,
HEALTHCARE ACQUISITION CORP., a Delaware
corporation
By: /s/ Jay M. Haft
------------------------------------
Jay M. Haft, Chairman of the Board
of Directors
AGREED AND ACCEPTED:
ENCORE ORTHOPEDICS, INC., a Texas corporation
By: /s/ Nicholas Cindrich
-----------------------------
Nicholas Cindrich, Chairman of the
Board of Directors and Chief Executive Officer
Date: October 11, 1996
---------------------------
<PAGE> 8
EXHIBIT A
List of Options granted at $5.00 per share
<TABLE>
<S> <C>
Dr. Burton Marsh 10,000
Dr. Kevin Coupe 5,000
Dr. James Duke 10,000
Williams Family 24,000
Orthosource, Inc. 15,000
Ken Palmer 7,500
Ally Medical, Inc. 25,000
Encore Arizona 10,000
Total Medical, Inc. 10,000
Downside Risk, Inc. 10,000
Encore Rocky Mountain 10,000
Enob, Inc. 10,000
Florida Representatives 6,000
Total Orthopedics, Inc. 30,000
</TABLE>
<PAGE> 1
Exhibit 99.1
FOR IMMEDIATE RELEASE
Healthcare Acquisition Corp. announces execution of Letter of Intent with
Encore Orthopedics, Inc.
Fort Lauderdale, Florida, October 17, 1996 -- Healthcare Acquisition Corp.
("HCAC") announced today that it has entered into a Letter of Intent with
Encore Orthopedics, Inc. ("Encore"). The Letter of Intent contemplates that
Encore will become a wholly owned subsidiary of HCAC.
HCAC is a public company organized for the purpose of acquiring or merging with
an operating business in the health care industry. Encore is a manufacturer and
world-wide distributor of orthopedic implants based in Austin, Texas. It is
listed as 398 in the Inc. 500 list of fastest growing private companies in the
United States. The transaction is subject, among other conditions, to
regulatory approval, execution of a definitive merger agreement between the
parties and approval by both company's shareholders. No further information is
available at this time.
